Intestinal Pathogenic Escherichia coli

Vaccines for Biodefense and Emerging and Neglected Diseases

Volumn , Issue , 2009, Pages 1013-1029

  Torres, Alfredo G ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879462534     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369408-9.00051-2     Document Type: Chapter

References (109)

1. Ahmed A., Li J., Shiloach Y., Robbins J.B., Szu S.C. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J. Infect. Dis. 2006, 193:515-521.
2. Altboum Z., Barry E.M., G.L., Galen J.E., Levine M.M. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect. Immun. 2001, 69:3150-3158.
3. AMA, ANA-ANF, CDC, CFSAN-FDA, and FSIS-USDA Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. MMWR Recomm. Rep. 2004; 53:1-33.
4. Barry E.M., Altboum Z., Losonsky G., Levine M.M. Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine 2003, 21:333-340.
5. Barry E.M., Wang J., Wu T., Davis T., Levine M.M. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 2006, 24:3727-3734.
6. Beatty M.E., Bopp C.A., Wells J.G., Greene K.D., Puhr N.D., Mintz E.D. Enterotoxin-producing Escherichia coli O169:H41, United States. Emerg. Infect. Dis. 2004, 10:518-521.
7. Bell B.P., Griffin P.M., Lozano P., Christie D.L., Kobayashi J.M., Tarr P.I. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997, 100:E12.
8. Bern C., Martines J., de Zoysa I., Glass R.I. The magnitude of the global problem of diarrhoeal disease: a ten-year update. Bull. World Health Organ. 1992, 70:705-714.
9. Boedeker E.C. Vaccines for enterotoxigenic Escherichia coli: current status. Curr. Opin. Gastroenterol. 2005, 21:15-19.
10. Bokete T.N., Whittam T.S., Wilson R.A., Clausen C.R., O'Callahan C.M., Mosely S.L., Fritsche T.R., Tarr P.I. Genetic and phenotypic analysis of Escherichia coli with enteropathogenic characteristics isolated from Seattle children. J. Infect. Dis. 1997, 175:1382-1389.
11. CDC. Travelers' diarrhea. Frequently asked questions. 2005.
12. Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food-10 states, 2006. MMWR Morb. Mortal. Wkly. Rep. 2007, 56:336-339. CDC.
13. Chart H., Smith H.R., Scotland S.M., Rowe B., Milford D.V., Taylor C.M. Serological identification of Escherichia coli O157:H7 infection in haemolytic uraemic syndrome. Lancet 1991, 337:138-140.
14. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Neogy P.K., Stanton B., Huda N., Khan M.U., Kay B.A., Khan M.R., et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli results of a large-scale field trial. J. Infect. Dis. 1988, 158:372-377.
15. Cravioto A., Tello A., Navarro A., Ruiz J., Villafan H., Uribe F., Eslava C. Association of Escherichia coli HEp-2 adherence patterns with type and duration of diarrhoea. Lancet 1991, 337:262-264.
16. de Souza Campos Fernandes R.C., Quintana Flores V.M., Sousa de Macedo Z., Medina-Acosta E. Coproantibodies to the enteropathogenic Escherichia coli vaccine candidates BfpA and EspB in breastfed and artificially fed children. Vaccine 2003, 21:1725-1731.
17. Donnenberg M.S. Enteropathogenic Escherichia coli. Infections of the Gastrointestinal Tract 1995, 709-726. Raven Press, New York, NY. M.J. Blaser, P.D. Smith, J.I. Ravdin, H.B. Greenberg, R.L. Guerrant (Eds.).
18. Donnenberg M.S., Tacket C.O., Losonsky G., Frankel G., Nataro J.P., Dougan G., Levine M.M. Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge. Infect. Immun. 1998, 66:52-58.
19. DuPont H.L. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 1997, 92:1962-1975.
20. DuPont H.L. What's new in enteric infectious diseases at home and abroad. Curr. Opin. Infect. Dis. 2005, 18:407-412.
21. Elsinghorst E.A., Kopecko D.J. Molecular cloning of epithelial cell invasion determinants from enterotoxigenic Escherichia coli. Infect. Immun. 1992, 60:2409-2417.
22. Elsinghorst E.A., Weitz J.A. Epithelial cell invasion and adherence directed by the enterotoxigenic Escherichia coli tib locus is associated with a 104-kilodalton outer membrane protein. Infect. Immun. 1994, 62:3463-3471.
23. Eriksson K., Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol. 2002, 14:666-672.
24. Escobar-Paramo P., Clermont O., Blanc-Potard A.B., Bui H., Le Bouguenec C., Denamur E. A specific genetic background is required for acquisition and expression of virulence factors in Escherichia coli. Mol. Biol. Evol. 2004, 21:1085-1094.
25. Forestier C., Meyer M., Favre-Bonte S., Rich C., Malpuech G., Le Bouguenec C., Sirot J., Joly B., De Champs C. Enteroadherent Escherichia coli and diarrhea in children: a prospective case-control study. J. Clin. Microbiol. 1996, 34:2897-2903.
26. Frenzen P.D., Drake A., Angulo F.J. Economic cost of illness due to Escherichia coli O157 infections in the United States. J. Food Prot. 2005, 68:2623-2630. Group E.I.P.F.W.
27. Gaastra W., Svennerholm A.M. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). TRENDS Microbiol. 1996, 4:444-452.
28. Gansheroff L.J., Wachtel M.R., O'Brien A.D. Decreased adherence of enterohemorrhagic Escherichia coli to HEp-2 cells in the presence of antibodies that recognize the C-terminal region of intimin. Infect. Immun. 1999, 67:6409-6417.
29. Girard M.P., Steele D., Chaignat C.L., Kieny M.P. A review of vaccine research and development: human enteric infections. Vaccine 2006, 24:2732-2750.
30. Gomes T.A.T., Rassi V., MacDonald K.L., Ramos S.R., Trabulsi L.R., Vieira M.A., Guth B.E., Candeias J.A., Ivey C., Toledo M.R., et al. Enteropathogens associated with acute diarrheal disease in urban infants in Sao Paulo, Brazil. J. Infect. Dis. 1991, 164:331-337.
31. Greenberg D.E., Jiang Z., Steffen R., Verenker M.P., DuPont H.L. Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J. Infect. Dis. 2002, 185:944-949.
32. Griffin P.M., Tauxe R.V. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 1991, 13:60-98.
33. Guerena-Burgueno F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., Roberts Z.J., Nesterova G.V., Alving C.R., Glenn G.M. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 2002, 70:1874-1880.
34. Haack J.P., Jelacic S., Besser T.E., Weinberger E., Kirk D.J., McKee G.L., Harrison S.M., Musgrave K.J., Miller G., Price T.H., Tarr P.I. Escherichia coli O157 exposure in Wyoming and Seattle: serologic evidence of rural risk. Emerg. Infect. Dis. 2003, 9:1226-1231.
35. Haberberger R.L., Mikhail I.A., Burans J.P., Hyams K.C., Glenn J.C., Diniega B.M., Sorgen S., Mansour N., Blacklow N.R., Woody J.N. Travelers' diarrhea among United States military personnel during joint American-Egyptian armed forces exercises in Cairo, Egypt. Mil. Med. 1991, 156:27-30.
36. Hall E.R., Wierzba T.F., Ahren C., Rao M.R., Bassily S., Francis W., Girgis F.Y., Safwat M., Lee Y.J., Svennerholm A.M., Clemens J.D., Savarino S.J. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine. Infect. Immun. 2001, 69:2853-2857.
37. Hancock D.D., Besser T.E., Rice D.H., Tarr P.I. Ecology of Escherichia coli O157:H7 in cattle and impact of management practices. Escherichia coli O157:H7 and other Shiga Toxin-Producing &E. coli Strains 1998, 85-91. ASM Press, Washington, DC. J.B. Kaper, A.D. O'Brien (Eds.).
38. Harrington S.M., Dudley E.G., Nataro J.P. Pathogenesis of enteroaggregative Escherichia coli infection. FEMS Microbiol. Lett. 2006, 254:12-18.
39. Henderson I.R., Czeczulin J., Eslava C., Noriega F., Nataro J.P. Characterization of pic, a secreted protease of Shigella flexneri and enteroaggregative Escherichia coli. Infect. Immun. 1999, 67:5587-5596.
40. Jallat C., Darfeuille-Michaud A., Rich C., Joly B. Survey of clinical isolates of diarrhoeogenic Escherichia coli: diffusely adhering E. coli strains with multiple adhesive factors. Res. Microbiol. 1994, 145:621-632.
41. Jallat C., Livrelli V., Darfeuille-Michaud A., Rich C., Joly B. Escherichia coli strains involved in diarrhea in France: high prevalence and heterogeneity of diffusely adhering strains. J. Clin. Microbiol. 1993, 31:2031-2037.
42. Jertborn M., Ahren C., Holmgren J., Svennerholm A.M. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. Vaccine 1998, 16:225-260.
43. Jordan D., McEwen S.A., Lammerding A.M., McNab W.B., Wilson J.B. Pre-slaughter control of Escherichia coli O157 in beef cattle: a simulation study. Prev. Vet. Med. 1999, 41:55-74.
44. Judge N.A., Mason H.S., O'Brien A.D. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infect. Immun. 2004, 72:168-175.
45. Kahali S., Sarkar B., Rajendran K., Khanam J., Yamasaki S., Nandy R.K., Bhattacharya S.K., Ramamurthy T. Virulence characteristics and molecular epidemiology of enteroaggregative Escherichia coli isolates from hospitalized diarrheal patients in Kolkata, India. J. Clin. Microbiol. 2004, 42:4111-4120.
46. Kaper J.B., Nataro J.P., Mobley H.L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2004, 2:123-140.
47. Karmali M.A. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 1989, 2:15-38.
48. Konadu E.Y., Parke J.C.J., Tran H.T., Bryla D.A., Robbins J.B., Szu S.C. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide- Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J. Infect. Dis. 1998, 177:383-387.
49. Lauterslager T.G., Florack D.E., van der Wal T.J., Molthoff J.W., Langeveld J.P., Bosch D., Boersma W.J., Hilgers L.A. Oral immunisation of naive and primed animals with transgenic potato tubers expressing LT-B. Vaccine 2001, 19:2749-2755.
50. Le Bouguenec C. Diarrhea-associated diffusely adherent Escherichia coli. Clin. Microbiol. Rev. 1999, 12:180-181.
51. Le Bouguenec C., Servin A.L. Diffusely adherent Escherichia coli strains expressing Afa/Dr adhesins (Afa/Dr DAEC): hitherto unrecognized pathogens. FEMS Microbiol. Lett. 2006, 256:185-194.
52. Levine M.M. Fimbriae (pili) as vaccines. Protein-Carbohydrate Interactions in Biological Systems: The Molecular Biology of Microbial Pathogenicity 1986, 143-145. Academic Press, Ltd, London, United Kingdom. D.L. Lark (Ed.).
53. Levine M.M., Edelman R. Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol. Rev. 1984, 6:31-51.
54. Levine M.M., Nataro J.P., Karch H., Baldini M.M., Kaper J.B., Black R.E., Clements M.L., O'Brien A.D. The diarrheal response of humans to some serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J. Infect. Dis. 1985, 152:550-559.
55. Levine M.M., Svennerholm A.-M. Enteric vaccines: present and future. Textbook of Travel Medicine and Health 2001, 252-263. BC Decker, New York. H.L. DuPont, H. Steffen (Eds.).
56. Lopes L.M., Fabbricotti S.H., Ferreira A.J., Kato M.A., Michalski J., Scaletsky I.C. Heterogeneity among strains of diffusely adherent Escherichia coli isolated in Brazil. J. Clin. Microbiol. 2005, 43:1968-1972.
57. Marcato P., Griener T.P., Mulvey G.L., Armstrong G.D. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. Infect. Immun. 2005, 73:6523-6529.
58. Marcato P., Mulvey G., Read R.J., Vander Helm K., Nation P.N., Armstrong G.D. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J. Infect. Dis. 2001, 183:435-443.
59. Martinez M.B., Taddei C.R., Ruiz-Tagle A., Trabulsi L.R., Giron J.A. Antibody response of children with enteropathogenic Escherichia coli infection to the bundle-forming pilus and locus of enterocyte effacement-encoded virulence determinants. J. Infect. Dis. 1999, 179:269-274.
60. Mellies J.L., Elliott S.J., Sperandio V., Donnenberg M.S., Kaper J.B. The Per regulon of enteropathogenic Escherichia coli: identification of a regulatory cascade and a novel transcriptional activator, the locus of enterocyte effacement (LEE)-encoded regulator (Ler). Mol. Microbiol. 1999, 33:296-306.
61. Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 1998, 11:142-201.
62. Nataro J.P., Steiner T., Guerrant R.L. Enteroaggregative Escherichia coli. Emerg. Infect. Dis. 1998, 4:251-261.
63. Nataro J.P., Yikang D., Cookson S., Cravioto A., Savarino S.J., Guers L.D., Levine M.M., Tacket C.O. Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J. Infect. Dis. 1995, 171:465-468.
64. Nguyen R.N., Taylor L.S., Tauschek M., Robins-Browne R.M. Atypical enteropathogenic Escherichia coli infection and prolonged diarrhea in children. Emerg. Infect. Dis. 2006, 12:597-603.
65. Okeke I.N., Nataro J.P. Enteroaggregative Escherichia coli. Lancet Infect. Dis. 2001, 1:304-313.
66. Parsot C. Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol. Lett. 2005, 252:11-18.
67. Peltola H., Siitonen A., Kyronseppa H., Simula I., Mattila L., Oksanen P., Kataja M.J., Cadoz M. Prevention of travelers' diarrhea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991, 338:1285-1289.
68. Poitrineau P., Forestier C., Meyer M., Jallat C., Rich C., Malpuech G., De Champs C. Retrospective case-control study of diffusely adhering Escherichia coli and clinical features in children with diarrhea. J. Clin. Microbiol. 1995, 33:1961-1962.
69. Potter A.A., Klashinsky S., Li Y., Frey E., Townsend H., Rogan D., Erickson G., Hinkley S., Klopfenstein T., Moxley R.A., Smith D.R., Finlay B.B. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 2004, 22:362-369.
70. Prats G., Llovet T. Enteroinvasive Escherichia coli Pathogenesis and epidemiology. Microbiologia 1995, 11:91-96.
71. Qadri F., Svennerholm A.M., Faruque A.S., Sack R.B. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin. Microbiol. Rev. 2005, 18:465-483.
72. Qadri F.A., Ahmed T., Ahmed F., Bradley Sack R., Sack D.A., Svennerholm A.M. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine 2003, 21:2394-2403.
73. Rangel J.M., Sparling P.H., Crowe C., Griffin P.M., Swerdlow D.L. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg. Infect. Dis. 2005, 11:603-609.
74. Reymond D., Johnson R.D., Karmali M.A., Petric M., Winkler M., Johnson S., Rahn K., Renwick S., Wilson J., Clarke R.C., Spika J. Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents. J. Clin. Microbiol. 1996, 34:2053-2057.
75. Riley L.W., Remis R.S., Helgerson S.D., McGee H.B., Wells J.G., Davis B.R., Hebert R.J., Olcott E.S., Johnson L.M., Hargrett N.T., Blake P.A., Cohen M.L. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 1983, 308:681-685.
76. Robinson C.M., Sinclair J.F., Smith M.J., O'Brien A.D. Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization. Proc. Natl. Acad. Sci. USA 2006, 103:9667-9672.
77. Rogan, D. Vaccination reduces shedding and colonization of E. coli 0157:H7 in cattle. In 4th International Conference on Vaccines for Enteric Diseases Lisbon, Portugal., 2007.
78. Rothbaum R., McAdams A.J., Giannella R., Partin J.C. A clinicopathological study of enterocyte-adherent Escherichia coli: a cause of protracted diarrhea in infants. Gastroenterology 1982, 83:441-454.
79. Savarino S.J., Hall E.R., Bassily S., Wierzba T.F., Youssef F.G., Peruski L.F.J., Abu-Elyazeed R., Rao M., Francis W.M., El Mohamady H., Safwat M., Naficy A.B., Svennerholm A.M., Jertborn M., Lee Y.J., Clemens J.D., Group P.S. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr. Infect. Dis. J. 2002, 21:322-330.
80. Scaletsky I.C., Fabbricotti S.H., Carvalho R.L., Nunes C.R., Maranhao H.S., Morais M.B., Fagundes-Neto U. Diffusely adherent Escherichia coli as a cause of acute diarrhea in young children in Northeast Brazil: a case-control study. J. Clin. Microbiol. 2002, 40:645-648.
81. Scaletsky I.C., Silva M.L., Trabulsi L.R. Distinctive patterns of adherence of enteropathogenic Escherichia coli. Infect. Immun. 1984, 45:534-536.
82. Scerpella E.G., Sanchez J.L., Mathewson J.J., Torres-Cordero J.V., Sadoff J.C., Svennerholm A.M., DuPont H.L., Taylor D.N., Ericsson C.D. Safety, immunogenicity, and protective efficacy of the wholecell/recombinant B subunit (WC/rBS) oral cholera vaccine against travelers' diarrhea. J. Travel Med. 1995, 2:22-27.
83. Scotland S.M., Smith H.R., Cheasty T., Said B., Willshaw G.A., Stokes N., Rowe B. Use of gene probes and adhesion tests to characterize Escherichia coli belonging to enteropathogenic serogroups isolated in the United Kingdom. J. Med. Microbiol. 1996, 44:438-443.
84. Sears C.L., Kaper J.B. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol. Rev. 1996, 60:167-215.
85. Senerwa D., Olsvik O., Mutanda L.N., Lindqvist K.J., Gathuma J.M., Fossum K., Wachsmuth K. Enteropathogenic Escherichia coli serotype O111:HNT isolated from preterm neonates in Nairobi, Kenya. J. Clin. Microbiol. 1989, 27:1307-1311.
86. Steffen R., Castelli F., Dieter Nothdurft H., Rombo L., Jane Zuckerman N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J. Travel Med. 2005, 12:102-107.
87. Steiner T.S., Lima A.A.M., Nataro J.P., Guerrant R.L. Enteroaggregative Escherichia coli produce intestinal inflammation and growth impairment and cause interleukin-8 release from intestinal epithelial cells. J. Infect. Dis. 1998, 177:88-96.
88. Steiner T.S., Nataro J.P., Poteet-Smith C.E., Smith J.A., Guerrant R.L. Enteroaggregative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. J. Clin. Invest. 2000, 105:1769-1777.
89. Svennerholm A.M., Ahren C., Jertborn M. Vaccines against enterotoxigenic Escherichia coli infections. I. Oral inactivated vaccines against enterotoxigenic Escherichia coli. New Generation Vaccines 1997, 865-873. Marcel Dekker, Inc, New York, NY. M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon (Eds.).
90. Svennerholm A.-M., Savarino S.J. Oral inactivated whole cell B subunit combination vaccine against enterotoxigenic Escherichia coli. New Generation Vaccines 2004, Marcel Dekker, New York, NY. M.M. Levine, J.B. Kaper, R. Rappuoli, M.A. Liu, M.F. Good (Eds.).
91. Svennerholm A.M., Steele D. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract. Res. Clin. Gastroenterol. 2004, 18:421-445.
92. Tacket C.O. Plant-derived vaccines against diarrhoeal diseases. Exp. Opin. Biol. Ther. 2004, 4:719-728.
93. Tacket C.O., Levine M.M. Vaccines against enterotoxigenic Escherichia coli infections. II. Live oral vaccines and subunit (purified fimbriae and toxin subunit vaccines). New Generation Vaccines 1997, 875-883. Marcel Dekker, Inc, New York, NY. M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon (Eds.).
94. Tesh V.L., O'Brien A.D. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol. Microbiol. 1991, 5:1817-1822.
95. Toledo M.R.F., Alvariza M.C.B., Murahovschi J., Ramos S.R.T.S., Trabulsi L.R. Enteropathogenic Escherichia coli serotypes and endemic diarrhea in infants. Infect. Immun. 1983, 39:586-589.
96. Torres A.G., Kaper J.B. PAIs of intestinal E. coli. Pathogenicity Islands (PAIs) and the Evolution of Pathogenic Microbes 2001, Vol. 1:31-48. Springer-Verlag, Berlin. J. Hacker, J.B. Kaper (Eds.).
97. Torres A.G., Zhou X., Kaper J.B. Adherence of diarrheagenic Escherichia coli strains to epithelial cells. Infect. Immun. 2005, 73:18-29.
98. Trabulsi L.R., Keller R., Tardelli Gomes T.A. Typical and atypical enteropathogenic Escherichia coli. Emerg. Infect. Dis. 2002, 8:508-513.
99. Turner A.K., Beavis J.C., Stephens J.C., Greenwood J., Gewert C., Thomas N., Deary A., Casula G., Daley A., Kelly P., Randall R., Darsley M.J. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Infect. Immun. 2006, 74:1062-1071.
100. Turner A.K., Terry T.D., Sack D.A., Londono-Arcila P., Darsley M.J. Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. Infect. Immun. 2001, 69:4969-4979.
101. Van Donkersgoed J., Hancock D., Rogan D., Potter A.A. Escherichia coli O157:H7 vaccine field trial in 9 feedlots in Alberta and Saskatchewan. Can. Vet. J. 2005, 46:724-728.
102. Wanke C.A., Gerrior J., Blais V., Mayer H., Acheson D. Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus. J. Infect. Dis. 1998, 178:1369-1372.
103. Wen S.X., Teel L.D., Judge N.A., O'Brien A.D. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc. Natl. Acad. Sci. USA 2006, 103:7082-7087.
104. Wiedermann G., Kollaritsch H., Kundi M., Svennerholm A.M., Bjare U. Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). J. Travel. Med. 2000, 7:27-29.
105. Wilson A., Evans J., Chart H., Cheasty T., Wheeler J.G., Tompkins D., Smith H.R. Characterization of strains of enteroaggregative Escherichia coli isolated during the infectious intestinal disease study in England. Eur. J. Epidemiol. 2001, 17:1125-1130.
106. Wong C.A., Jelacic S., Habeeb R.L., Watkins S.L., Tarr P.I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 2000, 342:1930-1936.
107. Zhao T., Doyle M.P., Harmon B.G., Brown C.A., Mueller P.O., Parks A.H. Reduction of carriage of enterohemorrhagic Escherichia coli O157:H7 in cattle by inoculation with probiotic bacteria. J. Clin. Microbiol. 1998, 36:641-647.
108. Zhu C., Feng S., Thate T.E., Kaper J.B., Boedeker E.C. Towards a vaccine for attaching/effacing Escherichia coli: a LEE encoded regulator (ler) mutant of rabbit enteropathogenic Escherichia coli is attenuated, immunogenic, and protects rabbits from lethal challenge with the wild-type virulent strain. Vaccine 2006, 24:3845-3855.
109. Zhu C., Feng S., Yang Z., Davis K., Rios H., Kaper J.B., Boedeker E.C. LEE-encoded regulator (Ler) mutants elicit serotype-specific protection, but not cross protection, against attaching and effacing E. coli strains. Vaccine 2007, 25:1884-1892.